Vor Biopharma Valuation

Is VOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VOR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VOR?

Key metric: As VOR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VOR. This is calculated by dividing VOR's market cap by their current book value.
What is VOR's PB Ratio?
PB Ratio0.7x
BookUS$72.96m
Market CapUS$54.25m

Price to Book Ratio vs Peers

How does VOR's PB Ratio compare to its peers?

The above table shows the PB ratio for VOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1x
CNTB Connect Biopharma Holdings
0.5x-15.9%US$55.3m
UNCY Unicycive Therapeutics
2x58.8%US$55.0m
FIXX Homology Medicines
0.7xn/aUS$54.3m
BNR Burning Rock Biotech
0.6xn/aUS$57.4m
VOR Vor Biopharma
0.7x9.8%US$54.3m

Price-To-Book vs Peers: VOR is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (1x).


Price to Book Ratio vs Industry

How does VOR's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$554.58m
IMAB I-Mab
0.4x1.8%US$76.59m
ACET Adicet Bio
0.4x6.7%US$74.16m
MGX Metagenomi
0.3x-23.2%US$70.73m
VOR 0.7xIndustry Avg. 1.9xNo. of Companies81PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VOR is good value based on its Price-To-Book Ratio (0.7x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is VOR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VOR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VOR's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.79
US$11.92
+1,409.0%
38.3%US$18.00US$3.00n/a8
Nov ’25US$0.80
US$13.19
+1,538.6%
41.6%US$22.00US$3.00n/a8
Oct ’25US$0.64
US$13.19
+1,967.0%
41.6%US$22.00US$3.00n/a8
Sep ’25US$0.87
US$13.19
+1,408.5%
41.6%US$22.00US$3.00n/a8
Aug ’25US$0.94
US$14.06
+1,396.0%
29.9%US$22.00US$10.00n/a8
Jul ’25US$0.99
US$14.06
+1,321.5%
29.9%US$22.00US$10.00n/a8
Jun ’25US$1.35
US$14.06
+941.7%
29.9%US$22.00US$10.00n/a8
May ’25US$1.77
US$14.69
+729.8%
26.6%US$22.00US$10.00n/a8
Apr ’25US$2.20
US$14.69
+567.6%
26.6%US$22.00US$10.00n/a8
Mar ’25US$2.27
US$15.44
+580.1%
25.3%US$22.00US$10.00n/a8
Feb ’25US$2.35
US$15.07
+541.3%
26.8%US$22.00US$10.00n/a7
Jan ’25US$2.25
US$15.07
+569.8%
26.8%US$22.00US$10.00n/a7
Dec ’24US$1.92
US$15.07
+685.0%
26.8%US$22.00US$10.00n/a7
Nov ’24US$1.66
US$15.07
+810.7%
26.8%US$22.00US$10.00US$0.807
Oct ’24US$2.12
US$15.07
+610.9%
26.8%US$22.00US$10.00US$0.647
Sep ’24US$2.67
US$13.75
+415.0%
37.4%US$22.00US$4.50US$0.878
Aug ’24US$3.17
US$14.81
+367.3%
34.4%US$22.00US$5.00US$0.948
Jul ’24US$3.09
US$14.81
+379.4%
34.4%US$22.00US$5.00US$0.998
Jun ’24US$4.74
US$14.81
+212.5%
34.4%US$22.00US$5.00US$1.358
May ’24US$4.29
US$14.82
+245.5%
34.4%US$22.00US$5.00US$1.778
Apr ’24US$5.38
US$14.82
+175.5%
34.4%US$22.00US$5.00US$2.208
Mar ’24US$5.51
US$17.88
+224.4%
49.2%US$38.00US$5.00US$2.278
Feb ’24US$5.29
US$17.88
+237.9%
49.2%US$38.00US$5.00US$2.358
Jan ’24US$6.65
US$18.25
+174.4%
47.1%US$38.00US$5.00US$2.258
Dec ’23US$4.75
US$18.13
+281.6%
48.5%US$38.00US$4.00US$1.928
Nov ’23US$4.69
US$21.13
+350.4%
43.8%US$38.00US$4.00US$1.668

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies